All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Mylotarg re-submitted to the FDA and EMA for regulatory review in AML

By Cynthia Umukoro

Share:

Feb 3, 2017


Antibody-Drug Conjugate (ADC) Mylotarg has been re-submitted for regulatory review at the U.S Food & Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of Acute Myeloid Leukemia (AML). Mylotarg was voluntarily withdrawn from market on October 15 2010 for the treatment of AML patients. 

ADC Mylotarg (gemtuzumab ozogamicin) is an antibody-targeted chemotherapeutic agent consisting of a humanized murine CD33 antibody. Since it is a humanized anti-CD33 monoclonal antibody, it is highly specific for targeting leukemic blasts. Mylotarg binds to, and is internalized by, tumor cells expressing CD33. As a result, this ADC can then dispense the anti-tumor antibiotic calicheamicin to CD33-expressing tumor cells1.

According to Biopharma, the FDA has accepted to review the submission of a Biologics Licence application for the ADC based on the data obtained from the phase III ALFA-701 study. Data from the ALFA-701 study showed that combination of Mylotarg with standard chemotherapy regimen in adult AML patients significantly improved 3-year Event Free Survival (EFS) and Relapse Free Survival (RFS) compared to chemotherapy alone2.

Currently, Mylotarg is being explored in multiple clinical trial studies in AML, Acute Promyelocytic Leukemia (APL), and Myelodysplastic Syndrome (MDS) patients.

References